PR Newswire: nyheter distribution, inriktning och uppföljning

'The Global Companion Diagnostic Market Will be Worth $19.3bn by 2023' Says Visiongain

Share with Twitter Share with LinkedIn

LONDON, January 22, 2013 /PRNewswire/ --

A new report by visiongain, a London-based business information provider, predicts that the global market for companion diagnostics will be worth $19.3bn by 2023. The market generated sales of $1.6bn in 2011.

The companion diagnostics market has experienced significant growth in recent years and has become one of the most promising areas within the IVD market. The number of partnerships between pharmaceutical companies and diagnostic manufacturers will continue to increase significantly over the forecast period given the array of benefits that these tests offer, visiongain predicts. Technological advancements in the field, including the discovery of new biomarkers and the development of new molecular tests, has helped propel the companion diagnostics market which is clearly evidenced by the vast number of drugs in development that have an associated biomarker programme. The market will be driven by the increasing development and use of biomarkers as well as the progressive decrease in costs of sequencing technologies. Biomarkers are now being employed at early stages of drug discovery and development, with many being increasingly developed in to companion diagnostic tests.

Rodrigo Gutierrez Gamboa, healthcare industry analyst, says "M&A activity in the companion diagnostics market has experienced explosive growth in recent years, and we expect this trend to continue as most pharmaceutical companies do not have an in-house diagnostic capability for either the development of a companion diagnostic or the commercialisation of the test once the drug is approved. Furthermore, in the last few years, most pharmaceutical companies have adopted new projects and strategies to develop companion diagnostic products. It seems most of these companies have begun to shift away from the blockbuster business model and realised that in order to be more effective, and save money, new drugs will have to be more personalised. Oncology remains the dominant field in the market; however, many of the leading companies are now reported to be working to develop companion diagnostics in other therapeutic areas including neurological, autoimmune, inflammatory and cardiovascular diseases."

Visiongain's research also suggests that the world companion diagnostics market will benefit from a positive reimbursement outlook in key regional markets, primarily due to the cost-effective nature of the tests. Visiongain predicts that this market will grow fast to 2023. The future of companion diagnostics appears promising and has significant potential for growth owing to the increasing demand for safer and more effective therapies. This new report adds to visiongain's wide range of analytical reports in healthcare and other industry areas.

For further information concerning the Visiongain's Medical Device Leader Series - Top Companion Diagnostic Companies 2013-2023 report please visit http://www.visiongain.com/Report/962/Medical-Device-Leader-Series-Top-Companion-Diagnostic-Companies-2013-2023

Contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44(0)20-7336-6100

Companies Listed

Abbott
Alere
ARCA Biopharma
ARGENE
AstraZeneca
Bayer
Beckman Coulter
BioMarin Pharmaceutical
bioMerieux
Biocartis
Biomonitor
Boehringer Ingelheim
Brain Resource Company
Bristol-Myers Squibb
CancerGuide Diagnostics
Caprion Proteomics
Caris Life Sciences
Celldex Therapeutics
Cellestis
Cephalon
Cepheid
Clearstone Central Laboratories
Clinical Reference Laboratory
CompanDX
Compendia Bioscience
Crescendo Bioscience
Curidium Medica
Dako
DiagnoCure
DxS
Eli Lilly
Endocyte
Epitomics
Exosome Diagnostics
Explera
Flagship Biosciences
Foundation Medicine
Genfit
GenMark Diagnostics
Genomic Health
Genzyme Genetics
GlaxoSmithKline
HistologiX
Hologic
Ibis Biosciences
InDex Pharmaceuticals
Invivoscribe Technologies
Ipsen
Ipsogen
Johnson and Johnson
Knome
Lab21
LabCorp
Laboratory for Personalized Molecular Medicine
Life Technologies
MDxHealth
Medco Health Sciences
Merck
MolecularMD
Monogram Biosciences
Myriad Genetics
Nanosphere
Navigenics
Oncomed
Opko Health
Oxford BioTherapeutics
Pfizer
PharmaMar
Progenika Biopharma
Prometheus
QIAGEN
Quest Diagnostics
Quintiles Transnational Corporation
Randox Pharma Services
RiboMed Biotechnologies
Roche
SABioscience Corporation
Saladax Biomedical
Siemens
Signal Genetics
Sirius Genomics
Skyline Diagnostics
STARLIMS Technologies
SterilMed
Synthes
Takeda
Target Discovery
TcLand Expression
Theranostics (NZ)
Theranostics Health
TIB MolBiol
Tocagen
Tragara Pharmaceuticals
Transgene
Transgenomic
TrimGen Corporation
Unilabs
ViiV Healthcare
Weisenthal Cancer Group
Zinfandel

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
 


SOURCE Visiongain



Journalister och bloggare

Besök PR Newswire för journalister för utsläpp, foton och anpassas matar bara för Media.

Visa och hämta arkiverade video Innehållet distribueras av MultiVu på Den digitala Center.

Share with Twitter Share with LinkedIn
 

Skapa innehåll för din webbplats

Förbättra din webbplats eller blogg med PR Newswires skräddarsydda nyhetsflöden.
börja idag.

 

 
 
 

Kontakta PR Newswire

Skicka oss ett mail till stockholm@prnewswire.se eller ring oss på +46 (0)8 1200 1300

 

 
 
 

Bli en PR Newswire kund

Begär mer information , se PR Newswire produkter & tjänster eller ring oss på +46 (0)8 1200 1300

 

 
 
  1. Produkter & tjänster
  2. Pressmeddelanden
  3. Kontakta PR Newswire